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Patients with active acromegaly are
at high risk of 25(OH)D deficiency
Jowita Halupczok- _Zyła, Aleksandra Jawiarczyk-Przybyłowska and Marek Bolanowski*
Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland
Acromegaly is a chronic disease characterized by hypersecretion of growth hormone (GH)
and insulin-like growth factor 1 (IGF-1). Electrolyte disturbances such as hypercalcemia
and hyperphosphatemia are reported in patients with this disorder. There is limited data
on vitamin D status in subjects with acromegaly. The aim of the study was to determine
calcium, inorganic phosphate, magnesium, alkaline phosphatase, and 25(OH)D levels
with regard to the activity of the disease. We also studied correlations of 25(OH)D and IGF-
1, GH, bodymass, body mass index, and age. A study group consisted of 55 acromegalic
patients, and was divided into three subgroups: active acromegaly (AA), well-controlled
acromegaly (WCA), cured acromegaly (CA). We enrolled 29 healthy subjects to a control
group (CG). Vitamin D deficiency was recorded in all AA patients, 13 WCA patients
(92.86%), 10 CA patients (62.5%), and 13 controls (54.17%). The highest 25(OH)D levels
were found in the CG group and the lowest in the AA group (p=0.012). The dose
of octreotide did not influence serum 25(OH)D levels. A significant positive correlation
between IGF-1 and 25(OH)D levels was observed in the AA group (r=0.58, p=0.024).
Inorganic phosphate levels were the highest in the AA group. In conclusion, active
acromegalic patients have lower 25(OH)D levels in comparison with the CG and are at
higher risk of vitamin D deficiency.
Keywords: acromegaly, GH, IGF-1, vitamin D, calcium, phosphate
Introduction
Acromegaly is a rare, chronic disease caused by hypersecretion of growth hormone (GH), usually
from a pituitary adenoma. Most GH effects are mediated by insulin-like growth factor 1 (IGF-
1), which is synthesized mainly in the liver and also in peripheral tissues (1). An association
between GH/IGF-1 axis and vitamin D has been studied over past years (1–7). It is thought that
vitamin D stimulates production of IGF-1 and IGF binding protein-3 (IGFBP-3) in the liver by
direct transcription regulation and/or by enhancing GH stimulation. Furthermore, IGF-1 causes
an increase in 1,25-dihydroxyvitamin D [1,25(OH)2D] levels by stimulating the expression and
activity of the 1a-hydroxylase in the kidney, which leads to an altered calcium–phosphate balance
in uncontrolled acromegaly (4, 8).
Exposure to ultraviolet (UV) radiation in sunlight initiates production of previtamin D3 from
7-dehydrocholesterol (provitamin D3). Previtamin D3 undergoes rapid thermal isomerization to
cholecalciferol (vitamin D3) (9). After synthesis in the skin (cholecarciferol) or ingestion with
the diet (ergocalciferol and cholecalciferol), vitamin D is hydroxylated to 25-hydroxyvitamin D
[25(OH)D] in the liver. The total 25-hydroxyvitamin D refers to the sum of vitamin D2 and D3
25-hydroxymetabolites. The second hydroxylation takes place mainly in the kidney and 25(OH)D is
converted to its biologically active form [1,25(OH)2D] (8–10). Other cell types such as keratinocytes,
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activated macrophages, bone, breast, prostate, and brain cells
can also synthesize [1,25(OH)2D] (9, 11). Vitamin D receptor
(VDR) is expressed in most tissues throughout the body (12).
The combined presence of 1a-hydroxylase and VDR in several
tissues suggests a paracrine/autocrine role of [1,25(OH)2D3] (9–
11). There is agreement that 25(OH)D is regarded as the best
measurement of overall vitamin D (8, 10, 12).
Until recently, vitamin D deficiency was associatedmainly with
impaired bonemineralization leading to conditions such as rickets
in children, osteomalacia, osteoporosis, myopathy, and increased
fracture risk (9, 12, 13). It is also reported that fracture risk is high
in patients with acromegaly (14). During the last decades, research
has brought evidence that vitamin D acts like a pleiotropic hor-
mone (8, 15). VitaminD deficiency is considered to be a risk factor
of cardiovascular disease, cancers, diabetes, respiratory disease,
and all-cause mortality (12, 13, 16). Moreover, normal vitamin D
status seems to be protective against infectious diseases, autoim-
mune diseases, neurocognitive dysfunction and mental illness,
infertility, adverse pregnancy, and birth outcomes (16).
The aim of our study was to determine vitamin D status and
calcium/phosphate homeostasis in patients with acromegaly with
regard to the activity of the disease and to evaluate the association
between vitamin D and GH, IGF-1, body mass, BMI, and age.
Materials and Methods
We enrolled 55 patients with acromegaly aged 23–83 years (16
males and 39 females;mean age 50.85 5.24 years). Based on clin-
ical findings and hormonal evaluation (GH, IGF-1), we divided
the study group into three subgroups: (1) active acromegaly group
(AA), 20 patients; (2) well-controlled acromegaly group (WCA),
17 patients; (3) cured acromegaly (CA), 18 patients. Normal IGF-
1 values (sex- and age-matched) and GH levels during oral glu-
cose tolerance test (OGTT) lower than 1.0µg/l (ng/ml) were the
criteria used for classifying patients as cured or well-controlled.
Patients who had undergone successful surgical treatment were
assigned to the CA group. Subjects, after failed surgery, receiving
treatment with 10–30mg of long-acting octreotide (Sandostatin
LAR, Novartis) administered intramuscularly every 28 days were
recruited to the WCA group. Patients who did not meet criteria
for cured or WCA were included in the AA group. We selected a
control group (CG) of 29 patients aged 21–77 years (6 males and
23 females) by matching subjects and controls by sex and age. The
CG showed no clinical symptoms of acromegaly and had normal
IGF-1 (age- and sex-matched) and GH values. All subjects in AA
andWCA groups were treated with long-acting octreotide. In the
AA group, 2 subjects received 10mg dose, 5 subjects 20mg dose
and 13 subjects 30mg dose. Not all of the AA patients received
the dose of 30mg due to drug intolerance. In the WCA group, 6
patients received 20mg dose and 11 patients 30mg dose. Among
the study group, 23 patients required substitution therapy with
hydrocortisone and 22 with -thyroxine. There was no statistically
significant difference between the numbers of patients requiring
hormonal replacement therapy in each subgroup. Diabetes mel-
litus treated with oral hypoglycemic agents was observed in 13
study group patients. None of the patients received calcium or
vitamin D supplementation. All participants had normal renal
and hepatic function. For the purposes of statistical analysis, we
created three classifications. The first classification was based on
the degree of disease activity (AA; WCA; CA; CG). The sec-
ond classification was used to analyze the differences between
the AA group, patients with cured and WCA (WCA+CA) and
controls (CG). The third classification compared the study group
(AA+WCA+CA) and the CG. The study was approved by
ethics committee of Wroclaw Medical University. All patients
were recruited from the Department of Endocrinology, Diabetol-
ogy and Isotope Therapy, Wroclaw Medical University. Written
informed consent was obtained from all patients.
We recorded patients’ weight (kg) and height (m) and cal-
culated their body mass index (BMI). Fasting venous blood
samples were collected from all participants. We evaluated
adrenal, somatotropic, thyroid, and gonadal axes, and pro-
lactin (PRL). The adrenocorticotropic hormone (ACTH), cor-
tisol, GH, thyrotropic hormone (TSH), free triiodothyronine
(fT3) and free thyroxine (fT4), luteinizing hormone (LH),
follicle-stimulating hormone (FSH), estradiol (E2), total testos-
terone (T), and PRL were measured by chemiluminescence
immunoassay method using Immulite 2000 kits (DPC, Ger-
many or USA; Siemens, USA). Reference ranges were as
follows: ACTH 0–46 pg/ml; GH 0.06–5µg/l (ng/ml); TSH
0.4–4.0mIU/l; fT3 2,76–6,45 pmol/l; fT4 11.5–22.7 pmol/l; LH
postmenopausal women 11.3–39.8mIU/ml, women in follicu-
lar phase 1.1–11.6mIU/ml, men 0.8–7.6mIU/ml; FSH post-
menopausal women 9.7–111mIU/ml, women in follicular phase
2.8–11.3mIU/ml, men 0.7–11.1mUI/ml; E2 postmenopausal
women 30–140 pg/ml, women in follicular phase 0–160 pg/ml;
T women 0.2–0.8 ng/ml, men 1.29–7.67 ng/ml, PRL women
1.9–25 ng/ml, men 2.5–17 ng/ml. Cortisol levels were measured
by chemiluminescentmicroparticle immunoassay using Architect
i1000SR (Abbott Laboratories, Abbott Park, IL, USA). Reference
ranges: before 10 a.m. 3.7–19.4µg/dl; after 5 p.m. 2.9–17.3µg/dl.
Urine free cortisol excretion was measured using a radioim-
munoassaymethod (Immunotech, BeckmanCoulter Inc., Prague,
Czech Republic), reference range: 14.0–75.0µg/24 h.
Serum IGF-1 levels were assessed by radioimmunologic assay
using IGF-1-D-RIT-CT kit (BioSource Europe S.A., Nivelles, Bel-
gium); reference ranges were sex- and age-matched. IGF-1 levels
were expressed in relation to the upper limit of normal (ULN)
for age (patient’s IGF-1 concentration divided by IGF-1 upper
reference range limit matched for age). In the study group, we
assessed plasma GH concentrations at 0, 60, and 120min after
oral administration of 75 g glucose. Serum 25(OH)D levels were
measured in 45 study group patients (15 AA, 14 WCA, and
16 CA subjects) and 24 controls using radioimmunoassay kits
(DIAsource, ImmunoAssays S.A., Louvain-la-Neuve, Belgium),
reference range: 20–70 ng/ml (summer), 10–60 ng/ml (winter).
The intra- and inter-assay coefficients of variation (CVs) were
7.3 and 7.2%, respectively. Seasonality was based on the date
of blood sample collection. October–April period corresponded
to winter season and May–September period represented sum-
mer season. We used following ranges of 25(OH)D concentra-
tions indicating vitamin D deficiency [<20 ng/ml (<50 nmol/l)],
suboptimal status [20–30 ng/ml (50–75 nmol/l)], optimal status
[30–50 ng/ml (75–125 nmol/l)] (16). Serum calcium, inorganic
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TABLE 1 | Demographic characteristics of the study and control groups.
Group Sex (n) Age (years) Body mass (kg) Height (m) BMI (kg/m2)
Female Male
AA 10 10 50.8515.24 88.1021.89a 1.730.11b,c,d 29.315.18
WCA 3 14 55.3512.45 81.4714.44 1.650.09 29.734.73a
CA 15 3 54.0011.52 88.0014.59a 1.660.10 31.714.48a
CG 23 6 47.8615.70 74.7814.90 1.670.09 26.834.55
WCA+CA 18 17 54.6611.83 84.8314.68a 1.660.09 30.754.65a
AA+WCA+CA 28 27 53.2713.16 86.0217.52a 1.680.11 30.234.85a
AA, active acromegaly; WCA, well-controlled acromegaly; CA, cured acromegaly; CG, control group.
ap<0.05 compared to CG.
bp<0.05 compared to WCA.
cp<0.05 compared to CA.
dp<0.05 compared to WCA+CA.
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FIGURE 1 | Concentration of 25(OH)D with regard to the activity of acromegaly. AA, active acromegaly; WCA, well-controlled acromegaly; CA, cured
acromegaly; CG, control group.
phosphate, magnesium, and alkaline phosphatase were measured
using colorimetric assays on an Architect c4000 (Abbott Labora-
tories, Abbott Park, IL, USA). Reference ranges were as follows:
calcium 4.2–5.15mEq/l; inorganic phosphate 2.7–4.5mg/dl; mag-
nesium 1.6–2.6mg/dl; alkaline phosphatase 40–150 IU/l. Statisti-
cal analysis was performed using Statistica software for Windows,
version 7.0 (StatSoft, Tulsa, Oklahoma, USA). The mean, 95%
confidence interval, standard deviation, and median were deter-
mined for all variables. The Shapiro–Wilk’s test was used to test the
normality of the variables. Student’s t test was applied when nor-
mality was indicated. A Mann–Whitney U test was used for data
not normally distributed. Correlations were determined using
Pearson’s test or Spearman’s rank correlation test as appropriate
based on variable distribution. p values <0.05 were considered
statistically significant.
Results
The highest mean body mass was observed in the AA group
and the lowest in the CG group. We found statistically sig-
nificant differences between groups: AA and CG (p= 0.014);
CA and CG (p= 0.005); WCA+CA and CG (p= 0.009);
AA+WCA+CA and CG (p= 0.004). The CA group had the
highest mean BMI, while the CG had the lowest. The compar-
ison between the CG group and WCA, CA, WCA+CA and
AA+WCA+CA groups revealed statistically significant differ-
ences (p< 0.003, p= 0.001, p= 0.001, p= 0.003; respectively)
(Table 1).
Vitamin D deficiency occurred in all AA patients, 13 WCA
patients (92.86%), 10 CA patients (62.5%) and 13 controls
(54.17%). Suboptimal levels of vitamin Dwere found in oneWCA
patient (7.14%), six CA patients (37.5%), and nine CG patients
(37.5%). Only two CG patients (8.33%) showed optimal vitamin
D concentrations.
The highest 25(OH)D levels were found in the CG group
and the lowest in the AA group (the difference was statisti-
cally significant, p= 0.012) (Figure 1). In the WCA and CA
groups, 25(OH)D concentrations were also lower compared to
the CG group; however, the differences were not statistically
significant (p= 0.109, p= 0.473; respectively). The differences in
25(OH)D levels among the AA, WCA, and CA groups were not
statistically significant, although the highest levels of 25(OH)D
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were noted in the CA group. Based on the third classifica-
tion (AA+WCA+CA vs. CG), higher 25(OH)D concentrations
were found in CG group, the difference was statistically sig-
nificant (p= 0.047). Other comparisons (AA and WCA+CA,
WCA+CA and CG) did not reveal statistically significant dif-
ferences (Table 2). We found no seasonal variations in 25(OH)D
levels in the AA, AA+WCA+CA and CG groups. There was no
relationship between the dose of octreotide and serum 25(OH)D
levels.
A significant positive correlation between IGF-1 levels and
25(OH)D levels was noted only in the AA group (r= 0.580,
p= 0.024) (Figure 2). There was no correlation between the GH
levels at 0, 60, and 120min during OGTT and 25(OH)D levels.
We found negative correlation between age and 25(OH)D levels
in theCA,WCA+CAandAA+WCA+CAgroups (r= 0.686,
p= 0.05; r= 0.494, p= 0.006; r= 0.421, p= 0.004; respec-
tively). There was no correlation between body mass, BMI, and
25(OH)D levels.
We also investigated correlations between 25(OH)D and cal-
cium, inorganic phosphate, magnesium concentrations. There
were significant positive correlations between calcium levels and
25(OH)D levels in the WCA and WCA+CA groups (r= 0.697,
p= 0.025; r= 0.442, p= 0.039; respectively). Magnesium levels
correlated positively with 25(OH)D levels in the WCA group
(r= 0.847, p= 0.016).
Calcium concentrations were the highest in the AA group;
however, the differences were not statistically significant, as com-
pared to other groups. We did not find any significant differences
in magnesium levels among groups. Plasma levels of inorganic
phosphate were the highest in the AA group. We noted statisti-
cally significant differences in inorganic phosphate levels between
groups: AA and CG (p= 0.012), AA and WCA (p= 0.029), AA
and CA (p= 0.015), AA and WCA+CA (p= 0.006). We found
significant positive correlation between inorganic phosphate and
IGF-1 in the AA group (r= 0.582, p= 0.014) and between inor-
ganic phosphate and IGF-1 ULN in the AA+WCA+CA group
(r= 0.427; p= 0.004) (Figure 3). Inorganic phosphate levels cor-
related positively with GH concentrations at 0min in the CG
group (r= 0.516, p= 0.028). There were no correlations between
calcium levels, alkaline phosphatase levels and IGF-1 levels in
the AA group. We found negative correlation between calcium
levels and GH levels at 0min in the CA group (r= 0.641,
p= 0.014). PRL concentrations were higher in the AA, WCA,
and CA groups compared to controls. There were no signif-
icant differences in the levels of other hormones (data not
shown).
Discussion
We have not found any data on the prevalence of vitamin D
deficiency in patients with acromegaly. Vitamin D deficiency
and insufficiency are global health problem; however, optimal
ranges of vitamin D are still not clearly defined (10, 16). In our
study, all patients with AA demonstrated 25(OH)D deficiency,
whereas in the CG only 13 patients (54.17%). This may suggest
that patients with uncontrolled acromegaly are more prone to
develop 25(OH)D deficiency. Classification of vitamin D status TA
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FIGURE 2 | Correlation between 25(OH)D and IGF-1 in the active acromegaly group.
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FIGURE 3 | Correlation between inorganic phosphate and IGF-1 ULN
in the AA+WCA+CA group.
we used is similar to the Endocrine Society Clinical Practice
Guidelines where vitamin D deficiency is defined as a 25(OH)D
below 20 ng/ml and insufficiency as a 25(OH)D of 21–29 ng/ml
(17, 18). Epidemiological data on vitamin D status in Poland is
limited. In a recent, large cross-sectional study, 67.5% of the Polish
adult population had 25(OH)D level <20 ng/ml, 22.8%had subop-
timal level of 20–30 ng/ml and only 8.4% had optimal 25(OH)D
level (30–50 ng/ml) (19). Hypovitaminosis D is associated with
inadequate sunlight exposure, obesity, dark skin pigmentation,
fat malabsorption, nephrotic syndrome, renal failure, hepatic fail-
ure, andmedications (anticolvulsants, glucocorticoids, AIDS/HIV
drugs) (12, 20). 25(OH)D levels were lower in patients with AA
compared to the CG. This may be related to the higher body
mass in AA group. Płudowski et al. showed that high body mass
and high BMI are risk factors of vitamin D deficiency. They
found significantly lower 25(OH)D concentrations in patients
with obesity compared to patients with BMI <30 kg/m2 (19). It
is well-established that vitamin D deficiency is associated with
obesity. Vitamin D is fat-soluble and stored in adipose tissue.
Additionally, obese patients have less exposure to sunlight because
of lower exercise and mobility (15, 21). Negative correlations
between 25(OH)D and BMI, body mass were previously reported
(19). Although we are not able to confirm this fact, 25(OH)D
levels decrease with age due to less time spent outdoors and
decreased vitamin D production efficiency (22). We also demon-
strated negative correlation between age and 25(OH) levels (CA
and WCA+CA groups). In other study, the highest 25(OH)D
concentrations were reported in elderly patients (>70 years),
while the lowest in the patients aged 15–25 years. This might be
explained by the fact that elderly people often take vitamin D
supplements (19).
Long-term and short-term treatment with somatostatin
analogs in patients with acromegaly does not affect vitamin D
levels (23, 24). Somatostatin analogs cause impairment of fat
absorption which can lead to loss of fat-soluble vitamins (25).
This might also influence vitamin D status in patients with
active and WCA (AA and WCA groups). In our study, we found
no relationship between the dose of octreotide and 25(OH)D
concentrations.
Vitamin D and IGF-1 both have a broad spectrum of effects
and their interrelations are extremely complex (8). We showed
a positive correlation between IGF-1 and 25(OH)D levels in AA
patients. Several studies disclosed a positive correlation between
IGF-1 and 25(OH)D concentrations (7, 26–28). Hyppönen et al.
reported a positive association between 25(OH)D and IGF-1,
with a linear increase in IGF-1 until 25(OH)D concentrations
reached 75–85 nmol/l, after which this effect reached a plateau
(7). IGF-1 and 25(OH)D might up-regulate each other. 25(OH)D
can increase IGF-1 receptor expression, thus promoting IGF-1
action (28). Furthermore, an in vitro study on cultured human
fetal epiphyseal chondrocytes showed that vitamin D stimulates
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expression of several GH–IGF axis genes such as IGF-1, IGFBP-
3, and growth hormone receptor (GHR) (3). On the other hand,
IGF-1 increases vitamin D activity by stimulation of renal 1a-
hydroxylase (28). Although 25(OH)D levels were lower in the AA
group, suggesting high IGF-1 seems to be associated with low
25(OH)D levels, IGF-1 was positively correlated with 25(OH)D
in the AA group. These findings point out that the association
between IGF-1 and vitamin D status is more complex.
In our study, we did not find correlations between 25(OH)D
levels and GH levels at 0, 60, and 120min of the OGTT. It is
not clear if GH actions on 1,25(OH)2D renal production are
mediated by IGF-1 (6). In patients with AA, GH receptor antag-
onist (pegvisomant) administration resulted in normalization of
IGF-1 and 1,25(OH)2D decrease. Interestingly, 25(OH)D concen-
trations remained unaffected (29). GH replacement in healthy
adults increased 1,25(OH)2D levels (6, 30). In another study,
patients with acromegaly had significantly increased 1,25(OH)2D
concentrations, however there was no correlation between GH
and 1,25(OH)2D levels. This suggests that other factors may be
responsible for elevated 1,25(OH)2D (2).
We demonstrated a positive correlation between 25(OH)D
levels and calcium levels (in WCA and CA+WCA groups).
1,25(OH)2D regulates bone metabolism and stimulates intesti-
nal calcium and phosphate absorption and renal calcium reab-
sorption. Moreover, 1,25(OH)2D inhibits parathormone (PTH)
release from the parathyroid glands. Renal production of
1,25(OH)2D is therefore regulated by phosphate, PTH, and
fibroblast growth factor 23 (FGF-23) (8).
Hypercalcemia is rarely encountered in patients with
acromegaly and might be PTH-dependent or 1,25(OH)2D-
dependent (1, 31). GHexcess is also associatedwith hypercalciuria
and nephrolithiasis (31, 32). Kamenický et al. found that increased
production of calcitriol in acromegaly is responsible for hyper-
calciuria and increased fasting plasma calcium concentrations
(33). We did not observe any significant differences in calcium
levels among the groups. Hyperphosphatemia is a common
finding in patients with acromegaly (6). The highest inorganic
phosphate levels were observed in patients with AA (AA group).
We also found positive correlation between IGF-1 and phosphate
concentrations in the AA group. Bianda et al. reported that renal
phosphate reabsorption increases in response to GH treatment,
whereas this effect is not present during IGF-1 therapy. A direct
effect of GH on tubular transport of phosphate, stimulation of
local production of IGF-1 acting in a paracrine way or GH effects
via other local or systemic regulators might be the mechanisms
explaining this fact (6).
The limitation of our study is that we did not measure levels of
1,25(OH)2D, PTH, and FGF-23, which have a strong influence on
calcium/phosphate status.
In conclusion, patients with AA have lower 25(OH)D concen-
trations compared to controls and are at higher risk of vitamin D
deficiency. In AA IGF-1 concentrations correlate positively with
25(OH)D levels. Patients with AA present a tendency to higher
inorganic phosphate levels than healthy subjects. Further research
is needed to fully understand the complex interactions GH/IGF-1
axis and vitamin D.
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